Safety

Fuzeon (enfuvirtide) for injection

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)

December 2015

Summary View

ADVERSE REACTIONS

Post Marketing Experience

Skin and Subcutaneous Tissue Disorders

  • Cutaneous amyloidosis at the injection site

 

April 2011

Summary View 

5 WARNINGS AND PRECAUTIONS

5.3 Pneumonia
  • ...results of study NV17751...

 

Page Last Updated: 01/13/2016
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English